CURE PHARMACEUTICAL Corp

OXNARD, CA · Founded 2011 · Medtech · Public

Orodispersible dosage form technology platform for oral medications

Claim this profile

Follows are private to you and power your alerts

Updated · curepharmaceutical.com

Sector
Medtech
Headquarters
OXNARD, CA
Founded
2011
Latest Form D
$6M, Oct 2016
Total capital
$9.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$9.4M
7 Form D · last Oct 2016
120 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

20122013201420152016FEDERAL ↑EQUITY ↓Cumulative $9.4M1st Form D$959K2nd Form D$300K7th Form D$6M
20122013201420152016FEDERAL ↑EQUITY ↓Cumulative $9.4M7th Form D$6M

Latest events

  • Private capital raisedForm D · SEC · 7th filing$6M
  • Private capital raisedForm D · SEC · 6th filing$250K
  • Private capital raisedForm D · SEC · 5th filing$323K
  • Private capital raisedForm D · SEC · 4th filing$1.5M
  • Private capital raisedForm D · SEC · 3rd filing$80K
  • Private capital raisedForm D · SEC · 2nd filing$300K
  • Private capital raisedForm D · SEC · 1st filing$959K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Ed MaliskiDirectorNamed in SEC Form D filings
  • Edward MaliskiExecutive Officer, DirectorNamed in SEC Form D filings
  • Ian SephtonDirectorNamed in SEC Form D filings
  • Jonathan TurmanExecutive Officer, DirectorNamed in SEC Form D filings
  • Mark UdellExecutive OfficerNamed in SEC Form D filings
  • Rob DavidsonExecutive Officer, DirectorNamed in SEC Form D filings
Show all 9 people
  • Robert DavidsonExecutive Officer, DirectorNamed in SEC Form D filings
  • Vic BranstetterDirectorNamed in SEC Form D filings
  • Wayne NasbyDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 1
  • PendingApparatus, Composition, And Related Methods For Transdermal Delivery Of Active IngredientsUSPTOApplication PCTUS2012054795
  • Illumigyn Ltd.Similar federal contract value in Medtech · null in contracts
  • S4 Medical Corp.Similar federal contract value in Medtech · null in contracts
  • LeukoDx, Inc.Similar federal contract value in Medtech · null in contracts
  • Vivex Biomedical, Inc.Similar federal contract value in Medtech · null in contracts
  • SCIENTIFIC INTAKE LTD COSimilar federal contract value in Medtech · null in contracts
  • NOCIRA, LLCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .